Owkin
Private Company
Funding information not available
Overview
Founded in 2016 by an oncologist and a machine learning pioneer, Owkin is building an agentic AI infrastructure for biology, aiming to automate R&D and connect research directly to patient care. Its core platform, K Pro, is an AI agent designed to generate and validate therapeutic hypotheses using real-world patient data. The company is well-funded, has commercialized CE-marked diagnostics, and collaborates with a vast network of academic and pharmaceutical partners to advance precision medicine.
Technology Platform
Owkin builds Biological Artificial Superintelligence (BAS) using its K Pro AI agent, federated learning on real-world patient data, and a patient validation framework to automate drug discovery and connect research to clinical care.
Opportunities
Risk Factors
Competitive Landscape
Owkin competes with AI-driven biotechs like Recursion, Exscientia, and Insilico Medicine, as well as digital pathology AI companies. Its differentiation lies in its federated learning approach using real-world patient data, the Patient Validation framework, strategic pharma equity partnerships (Sanofi, BMS), and its focus on the K Pro agentic AI system.